Our model
The Science Behind Psilocybin Therapy
What that phrase actually means — and why we can prove it.
We are a clinically grounded psilocybin healing center. We are also a place that holds the spiritual dimensions of human experience with reverence. We do not believe these are opposites. The peer-reviewed literature agrees — and we built our model on what that literature shows.
The core insight
The mystical experience is not a side effect. It is the mechanism.
Across more than a decade of controlled clinical research, one finding has emerged with unusual consistency: the intensity of the spiritual or mystical experience during a psilocybin session is one of the strongest predictors of therapeutic outcome. This relationship has been demonstrated across depression, substance use disorders, and cancer-related existential distress.
In 10 of 12 psychedelic therapy studies reviewed, a significant association was found between the intensity of the mystical experience and symptom reduction.
Ko et al., Frontiers in Psychiatry, 2022 — systematic review
This is not an accident of methodology. It suggests that something about the experience itself — the feeling of unity, transcendence, interconnectedness, and deep meaning — is doing therapeutic work that pharmacology alone cannot explain. At Zephyr, we design our programs around this finding. We create the conditions for profound experience and we provide the clinical framework to make it last.
The evidence in numbers
What we measure — and why it matters
The spiritual dimensions of healing are quantifiable.
We use validated psychometric instruments to assess the dimensions of experience that matter most — not just symptom reduction, but meaning, connection, and spiritual well-being. These instruments have been developed and validated across controlled clinical trials and are part of our standard outcome tracking.
MEQ-30
Mystical Experience Questionnaire
Assesses seven domains: internal unity, external unity, noetic quality, sacredness, positive mood, transcendence of time/space, and ineffability.
Validated across five laboratory studies (n=184). Barrett et al., 2015
FACIT-Sp
Spiritual Well-Being Scale
Self-report measure of spiritual well-being used in cancer populations. In a phase II trial of 30 cancer patients with MDD, all three spiritual well-being factors improved significantly (p < 0.001), sustained through 8 weeks.
Shnayder et al., 2023
PEQ
Persisting Effects Questionnaire
Measures lasting psychological and spiritual changes attributed to the psilocybin experience at follow-up. MEQ subscales "Positive Mood" and "Mysticality" were associated with persisting positive effects at 3 months.
McCulloch et al., 2022
NIH-HEALS
Psycho-Social-Spiritual Healing
A 35-item measure assessing Connection, Reflection and Introspection, and Trust and Acceptance. All three factors improved significantly in cancer patients receiving psilocybin-assisted therapy.
Shnayder et al., 2023
The neuroscience
The brain science of transcendence.
The spiritual experience psilocybin occasions is not a subjective epiphenomenon — it is associated with specific, measurable changes in brain architecture. The research here is among the most reproducible in contemporary neuroscience.
What the experience actually involves
The phenomenology of a complete mystical experience.
Participants across controlled studies describe a consistent phenomenology — feelings of unity and interconnectedness, a sense of sacredness, emotions of joy, peace, and awe, transcendence of ordinary time and space, and a quality of ineffability — an experience that resists language but feels more real than ordinary reality.
The seven MEQ-30 domains
What a complete mystical experience encompasses
Internal unity
External unity
Noetic quality — a sense of encountering deep truth
Sacredness
Positive mood
Transcendence of time and space
Ineffability
Scoring ≥60% across all seven defines a "complete mystical experience" in the clinical literature. This threshold has been associated with the most durable therapeutic outcomes.
Why set and setting matter clinically
Context shapes outcome — the research is clear
A three-arm RCT combining psilocybin with meditation found that the magnitude of the mystical experience and the rate of ongoing meditation practice both independently predicted positive changes at 6 months. Preparation, facilitation quality, and integration are not wellness enhancements — they are active determinants of therapeutic outcome.
Griffiths et al., 2018
On the evidence and its limitations
We hold the research honestly. A 2024 Cochrane review noted that while psychedelics may induce spiritually significant experiences compared to active placebo, the overall evidence remains "very uncertain" due to small sample sizes, high risk of bias from the inherent difficulty of blinding in psychedelic trials, limited participant diversity, and predominantly US-based, white, educated populations. Most studies have been conducted by a small number of research groups. We present this evidence as a foundation — not a guarantee — and we invite you to read the underlying research yourself.
Key citations
- 1.
Griffiths RR et al. Psilocybin can occasion mystical-type experiences. Psychopharmacology. 2006.
- 2.
Griffiths RR et al. Psilocybin-occasioned mystical-type experiences: dose-related effects. Psychopharmacology. 2011.
- 3.
Griffiths R et al. Mystical-type experiences mediate attribution of personal meaning 14 months later. Journal of Psychopharmacology. 2008.
- 4.
Barrett FS et al. Validation of the Mystical Experience Questionnaire. Journal of Psychopharmacology. 2015.
- 5.
James E et al. Psilocybin occasioned mystical-type experiences. Human Psychopharmacology. 2020.
- 6.
Schipper S et al. Psychedelic-assisted therapy for anxiety, depression, existential distress. Cochrane Database. 2024.
- 7.
Shnayder S et al. Psilocybin-assisted therapy improves psycho-social-spiritual well-being. Journal of Affective Disorders. 2023.
- 8.
McCulloch DE et al. Psilocybin-induced mystical-type experiences and persisting positive effects. Frontiers in Pharmacology. 2022.
- 9.
Griffiths RR et al. Psilocybin with meditation and spiritual practices. Journal of Psychopharmacology. 2018.
- 10.
Agin-Liebes GI et al. Long-term follow-up: psilocybin-assisted psychotherapy in cancer. Journal of Psychopharmacology. 2020.
- 11.
Ko K et al. Psychedelics, mystical experience, and therapeutic efficacy. Frontiers in Psychiatry. 2022.
- 12.
Andersen KAA et al. Therapeutic effects of serotonergic psychedelics: systematic review. Acta Psychiatrica Scandinavica. 2021.
- 13.
Siegel JS et al. Psilocybin desynchronizes the human brain. Nature. 2024.
- 14.
Smigielski L et al. Psilocybin-assisted mindfulness training modulates default mode network. NeuroImage. 2019.
- 15.
Kometer M et al. Psilocybin-induced spiritual experiences associated with neuronal synchronization. Psychopharmacology. 2015.
- 16.
Stenbæk DS et al. Brain serotonin 2A receptor binding predicts mystical effects of psilocybin. Journal of Psychopharmacology. 2021.
- 17.
Ferreira AE, Reis-Pina P. Psychedelic-assisted therapy, spirituality, mystical experiences in life-threatening illness. Journal of Psychosomatic Research. 2025.
Ready to learn more?